We are dedicated to the discovery, development, and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.

Learn More


La Jolla is developing LJPC-401 for the potential treatment of iron overload, which occurs as a result of hereditary hemochromatosis (HH), a genetic deficiency of hepcidin, or as a result of frequent blood transfusions required to treat diseases such as beta thalassemia and sickle cell disease (SCD).

Learn More

scientist working at the laboratory

Our researchers are focused on expanding our pipeline by developing innovative new therapies...

Learn More

© 2018 La Jolla Pharmaceutical Company